ザルトリウス・ジャパン Product Lineup

In recent years, the development of monoclonal antibodies (mAb) as therapeutic agents has garnered attention. mAb is highly anticipated for the treatment of severe diseases such as cancer and other conditions that are difficult to treat. One reason for this is not only their high efficacy and low side effects but also their high specificity of response. Vaccines and effective antibody therapeutics play an essential role in suppressing the ongoing COVID-19 pandemic and newly emerging variants. Neutralizing antibodies are one example of molecules that play a decisive role in the development of vaccines and therapeutics, as they can bind to viruses and prevent infection. Neutralizing antibodies can be isolated from the plasma of recovered patients, and researchers worldwide are focusing on them to deepen the understanding of the mechanism of action (MOA) against the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. *You can download the English version of the catalog. *For more details, please refer to the PDF materials or feel free to contact us.

Chimeric antigen receptor T cell (CAR-T) therapy uses genetically modified T cells to fight cancer and holds the potential to revolutionize the medical landscape. However, it is challenging for researchers developing cell-based therapies to explore the complex immune system, especially when using traditional screening and profiling methods. Recently, advancements in assay technology have begun to significantly change the drug discovery and development of CAR-T. These technological advancements have enabled high-throughput, cost-effective analyses that provide speed and sensitivity, yielding deeper biologically relevant information and allowing for the rapid acquisition of practical results. *You can download the English version of the catalog. *For more details, please refer to the PDF materials or feel free to contact us.

This document introduces "Resolving the Bottlenecks in Data Analysis with iQue Forecyt Software." It includes "Comparison of Workflows," "Simple and Intuitive Experiment and Data Acquisition Setup," and "Powerful Data Analysis and Visualization Tools." This software allows you to obtain practical information to advance research topics more quickly than flow-based solutions. We encourage you to read it. 【Contents (partial)】 ■ Interactive assay development and analysis, and visualization of multi-parameter data ■ Comparison of workflows ■ Forecyt configuration options - expandable according to needs ■ Simple and intuitive experiment and data acquisition setup ■ Powerful data analysis and visualization tools *For more details, please refer to the PDF document or feel free to contact us.

This document presents the workflow and data for quantifying multiple AAV serotypes using the Octet AAVX biosensor on the Octet BioLayer Interferometry (BLI) label-free detection platform, facilitated by a simple direct quantification assay design. It also describes the main features and advantages of the AAVX biosensor. We encourage you to read this as a reference for product introduction. [Contents (excerpt)] ■ Summary ■ Introduction ■ Reagents and Testing Procedures ■ Matrix Interference Testing ■ Correlation between Octet AAVX Assay and ELISA *For more details, please refer to the PDF document or feel free to contact us.

This document is an application note that explains the biosimilar evaluation method using Fc gamma receptors and antigens through kinetics screening with "Octet" BLI. It introduces a method to determine the range of kinetic parameters for interactions with the target using a single concentration of analyte. Multiple analytes and ligands can be screened rapidly in a single measurement. By avoiding orthogonal formats with multiple parameters like ELISA, it is possible to advance only the molecules with the desired characteristics to downstream processes for further evaluation. [Contents] ■ Abstract ■ Introduction ■ Kinetics Screening - Optimization of Analyte Reactions ■ Materials and Methods ■ Results and Discussion ■ Conclusion *For more details, please download the PDF or feel free to contact us.

This document is an application note introducing the method for analyzing Fc gamma receptor-IgG interactions using the "Octet" biomolecular interaction analysis system. It presents a method for analyzing the interaction between the Fc region of IgG and Fc gamma receptors, which is crucial for initiating effector functions through binding to Fc gamma receptors expressed on the surface of immune effector cells, a key mechanism of action for therapeutic monoclonal antibodies. In addition to best practices for various biosensor formats, it also discusses assay optimization, curve fitting, and data analysis. [Contents (partial)] ■ Introduction ■ Selection of biosensors ■ Assay optimization ■ Data analysis ■ Evaluation of data quality and fitting ■ Measurement of Fc gamma receptor affinity in antibody engineering, equivalence testing, lot release assays, and QC *For more details, please download the PDF or feel free to contact us.

This document is an application note summarizing the analysis method for FcRn-antibody interactions using the "Octet" biomolecular interaction analysis system. The binding of the Fc region of human IgG antibodies to the neonatal Fc receptor (FcRn) affects the biological and pharmacological properties of antibodies, such as extending the half-life. By altering this binding, it is possible to extend or shorten the serum half-life of Fc-containing therapeutics, which can impact the efficacy of the drug. It includes recommendations on the selection of biosensors, assay optimization, data collection, curve fitting, and methods for result analysis. [Contents (partial)] ■ Introduction ■ Octet platform for FcRn-antibody interaction analysis ■ Selection of biosensors and assay direction ■ Assay optimization ■ Data analysis ■ Intra-assay and inter-assay precision *For more details, please download the PDF or feel free to contact us.